OREANDA-NEWS. Pfizer Inc. (NYSE: PFE) released today its 2015 integrated annual review, an in-depth look into the company’s financial, social and environmental performance. 2015 was marked by breakthrough scientific research, collaborations and partnerships. In the review, our scientists, researchers and business leaders offer in-depth looks at their projects and how they are working to discover and develop potential new medicines and vaccines to improve patient health.

“Our purpose at Pfizer is to bring therapies to patients that significantly improve their lives,” said Pfizer Chairman and Chief Executive Officer Ian C. Read. “Thanks to the more than 97,000 Pfizer colleagues around the world, we met our yearly commitments and continued to build the company's capabilities toward our goal to become the world's premier, innovative biopharmaceutical company by the end of this decade.”

As a result of our research as well as innovative collaborations with our peers and research partners, we saw great scientific progress across multiple therapeutic areas in 2015.

  • We advanced 39 potential new therapies in our R&D pipeline, representing the strongest progress in Pfizer's history.
  • Our research efforts in oncology have resulted in a broad and deep portfolio of compounds, including five immuno-oncology assets in human studies that have the potential to address the urgent therapeutic needs of cancer patients.
  • We advanced our investigational vaccines pipeline to research some of the most deadly infectious diseases that affect people of all ages.

In 2015, Pfizer made great strides to help ensure patients around the world have access to the Pfizer medicines and vaccines that are approved and available. “Our very license to operate depends on ensuring the medicines we make to improve patient health and wellbeing are available to as many people as possible,” commented Sally Susman, Executive Vice President, Corporate Affairs. “Patient assistance is not a program or catchphrase, it is a commitment.”

  • In 2015, we significantly expanded the eligibility of our U.S. patient assistance program, Pfizer RxPathways®. The program helped more than 250,000 people access our medicines during the year.
  • We continued global health partnerships including the International Trachoma Initiative at The Task Force for Global Health, which seeks to eliminate the world's leading cause of preventable blindness and marked 2015 with the 500 millionth dose donation of antibiotic Zithromax® (azithromycin).
  • 2015 was the 5th year of our partnership with Gavi, the Vaccine Alliance, in which we have pledged 740M doses of pneumococcal vaccines to immunize children in GAVI countries through 2025.
  • To address family planning needs of women in the developing world, our collaboration with the Bill & Melinda Gates Foundation and the Children's Investment Fund Foundation (CIFF) completed its first-full year, and was successful in helping broaden access to injectable contraceptive, Sayana® Press (medroxyprogesterone acetate), to tens of thousands of women across several countries in Africa and Asia.